

# Fact sheet

The Australian Injectable Drugs Handbook (AIDH) is an **essential frontline resource ensuring patient safety and quality care**, providing respected, unbiased, evidence-based, up-to-date information on **more than 500 injectable medicines**.

AIDH provides Australian **pharmacists, nurses and health professionals** working across **public and private hospitals, day procedure centres, infusion centres and aged care facilities** with a comprehensive one-stop reference that supports best clinical practice.

- The new 8<sup>th</sup> edition (AIDH8) has been **comprehensively updated** and includes **more than 50 new medicines**.
- AIDH8 contains more paediatric information than earlier editions; more than 150 monographs now include paediatric information.
- AIDH8 features **new sections** on **smart pumps, flushing of IV lines and devices**, management of **extravasation** and community-based parenteral antimicrobial therapy (**CoPAT**).

***View all new information and significant changes and full list of new drugs over page***

## Supporting best practice

- AIDH8 is Australia's **indispensable frontline nursing resource** to manage risk and ensure quality care in every hospital, in every ward in Australia.
- Every monograph has been reviewed by pharmacists and nurses to ensure information is correct, current and relevant to Australian practice.
- AIDH8 provides **stability data for 21 antimicrobials** most frequently used in the community setting, such as through **Hospital in the Home (HITH) services** or **OPAT programs**, crucial for ensuring the standard of care is no less than that provided in hospital.
- Ensure up-to-date copies of the 'yellow book' are within reach at all times in medicine preparation rooms, in theatres and at nursing stations.

## Minimising clinical risk

- Clear and concise preparation and administration instructions minimises the risk of incorrect preparation and medicine administration errors.
- High-risk drug monographs include safety information that should be considered before giving the injection to a patient.
- The AIDH8 online version will be live from 19th February. Ensure that the hard copies on the ward are also the 8<sup>th</sup> edition, There are significant differences in some monographs that may contribute to clinical risk.

# New information and significant changes

- **Blood products** have been extensively reviewed and expanded and are now listed in alphabetical order by brand. They can also be found by factor number in the index.
- **Allergy warnings** for penicillins, cephalosporins and carbapenems have been updated to reflect current consensus guidelines
- A warning about potential for permanent staining from **iron infusions**
- The following **monographs** have been **significantly revised**:
  - acetylcysteine
  - adrenaline (epinephrine)
  - argipressin (vasopressin)
  - chlorpromazine
  - dobutamine
  - dopamine
  - hydroxocobalamin
  - ipilimumab
  - isoprenaline
  - levosimendan
  - lidocaine
  - meropenem
  - metaraminol
  - milrinone
  - nivolumab
  - noradrenaline (norepinephrine)
  - tirofiban
  - tranexamic acid
- Some **monographs** have been **combined**:
  - The **epoetins** combined monograph includes epoetin alfa, epoetin beta, epoetin lambda, darbepoetin and methoxyepoetin beta.
  - **Filgrastim** (including biosimilars), **pegfilgrastim** and **lipegfilgrastim** have been combined into a single monograph. Lenograstim retains its own monograph.
  - The **follitropins** combined monograph includes follitropin alfa, follitropin beta, follitropin delta and corifollitropin alfa. It includes biosimilars and the combination product with lutropin alfa.
  - The **interferons** combined monograph includes interferon alfa-2a, interferon beta-1a, interferon beta-1b and interferon gamma-1b.
  - The **peginterferons** combined monograph includes peginterferon alfa 2a and peginterferon beta 1a.
- There are two monographs for insulins based on the intended route of administration:
  - **Subcutaneous route ONLY i.e. biphasic, intermediate-acting and long-acting insulins.**
  - **Intravenous OR subcutaneous route i.e. short acting and ultra-short acting insulins.**

---

## New drugs included in AIDH 8:

- Advate (octocog alfa)
- Adynovate (rurioctocog alfa pegol)
- Alfa-1 proteinase inhibitor
- Alirocumab
- Amoxicillin sodium with potassium clavulanate
- Alprolix (eftrenonocog alfa)
- Asfotase alfa
- Aspirin
- Atezolizumab
- Avelumab
- Benefix (nonacog alfa)
- Benralizumab
- Bezlotoxumab
- Blinatumomab
- Brivaracetam
- Carfilzomib
- Ceftazidime with avibactam
- Daratumumab
- Dulaglutide
- Dupilumab
- Durvalumab
- Eloctate (efmorococog alfa)
- Elotuzumab
- Erenumab
- Eribulin
- Evolocumab
- Feiba-NF (factor VIII inhibitor bypassing fraction)
- Ferric derisomaltose
- Follitropin delta
- Fosfomicin
- Galcanezumab
- Guselkumab
- Inotuzumab
- Insulin degludec and insulin aspart (Ryzodeg 70/30)
- Irinotecan liposomal
- Isavuconazole
- Ixekizumab
- Lipegfilgrastim
- Mepolizumab
- Methylene blue
- Nadroparin
- Nicardipine
- Nivolumab
- NovoThirteen (catridecagog)
- Obizur (susococog alfa)
- Ocrelizumab
- Paracetamol with ibuprofen
- Pegvisomant
- Peramivir
- Plitidepsin
- Pralatrexate
- Protein C
- Ramucirumab
- Ranibizumab
- Silibinin
- Siltuximab
- Sodium chloride 20%
- Teduglutide
- Tildrakizumab
- Tisagenlecleucel